For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...